Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Jul;62(1):96–99. doi: 10.1038/bjc.1990.236

The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors.

A Qayum 1, W Gullick 1, R C Clayton 1, K Sikora 1, J Waxman 1
PMCID: PMC1971749  PMID: 2117967

Abstract

We have investigated the possibility of a direct regulatory effect of gonadotrophin releasing hormone (GnRH) analogues on prostatic cancer cell growth. Here we report high affinity binding (Kd = 50 nM) of a GnRH analogue resulting in biphasic growth modulation of the human androgen-sensitive prostatic cancer cell line LNCaP. In contrast, the human androgen-insensitive prostatic cancer cell line DU145 showed low-affinity (Kd = 10 microM) binding without any biological response to the GnRH analogue. A GnRH-specific radioimmunoassay demonstrated GnRH-like immunoreactivity in the concentrated culture medium from both cell lines. Seventy-six human benign and malignant tumours were assayed following surgical resection. Nineteen of 22 (86%) malignant tumours and 49 of 54 (91%) benign tumours, exhibited high affinity GnRH-analogue binding. Fourteen of 19 (74%) malignant tumours and 17 of 49 (35%) benign tumours exhibiting high affinity binding contained GnRH-like immunoreactivity, suggesting that this system may be involved in prostatic epithelial cell growth in vivo.

Full text

PDF
96

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BURTON K. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J. 1956 Feb;62(2):315–323. doi: 10.1042/bj0620315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  3. Clayton R. N., Harwood J. P., Catt K. J. Gonadotropin-releasing hormone analogue binds to luteal cells and inhibits progesterone production. Nature. 1979 Nov 1;282(5734):90–92. doi: 10.1038/282090a0. [DOI] [PubMed] [Google Scholar]
  4. Clayton R. N., Katikineni M., Chan V., Dufau M. L., Catt K. J. Direct inhibition of testicular function by gonadotropin-releasing hormone: mediation by specific gonadotropin-releasing hormone receptors in interstitial cells. Proc Natl Acad Sci U S A. 1980 Aug;77(8):4459–4463. doi: 10.1073/pnas.77.8.4459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Eidne K. A., Flanagan C. A., Harris N. S., Millar R. P. Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J Clin Endocrinol Metab. 1987 Mar;64(3):425–432. doi: 10.1210/jcem-64-3-425. [DOI] [PubMed] [Google Scholar]
  6. Horoszewicz J. S., Leong S. S., Kawinski E., Karr J. P., Rosenthal H., Chu T. M., Mirand E. A., Murphy G. P. LNCaP model of human prostatic carcinoma. Cancer Res. 1983 Apr;43(4):1809–1818. [PubMed] [Google Scholar]
  7. Kadar T., Redding T. W., Ben-David M., Schally A. V. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin. Proc Natl Acad Sci U S A. 1988 Feb;85(3):890–894. doi: 10.1073/pnas.85.3.890. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kuhl H., Baumann R. New aspects of the physiological significance of LRH receptors of pituitary plasma membranes. Acta Endocrinol (Copenh) 1981 Jan;96(1):36–45. doi: 10.1530/acta.0.0960036. [DOI] [PubMed] [Google Scholar]
  9. Kuhl H., Taubert H. D. Inactivation of luteinizing hormone releasing hormone by rat hypothalamic L-cystine arylamidase. Acta Endocrinol (Copenh) 1975 Apr;78(4):634–648. doi: 10.1530/acta.0.0780634. [DOI] [PubMed] [Google Scholar]
  10. Miller W. R., Scott W. N., Morris R., Fraser H. M., Sharpe R. M. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature. 1985 Jan 17;313(5999):231–233. doi: 10.1038/313231a0. [DOI] [PubMed] [Google Scholar]
  11. Szende B., Zalatnai A., Schally A. V. Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin. Proc Natl Acad Sci U S A. 1989 Mar;86(5):1643–1647. doi: 10.1073/pnas.86.5.1643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Waxman J. Gonadotrophin hormone releasing analogues open new doors in cancer treatment. Br Med J (Clin Res Ed) 1987 Oct 31;295(6606):1084–1085. doi: 10.1136/bmj.295.6606.1084. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Waxman J., Man A., Hendry W. F., Whitfield H. N., Besser G. M., Tiptaft R. C., Paris A. M., Oliver R. T. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. Br Med J (Clin Res Ed) 1985 Nov 16;291(6506):1387–1388. doi: 10.1136/bmj.291.6506.1387. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES